Related Experiment Video

Updated: Aug 12, 2025

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.1K

Levofloxacin versus ceftriaxone and azithromycin for treating community-acquired pneumonia: a randomized clinical

Davood Yadegarynia1, Shabnam Tehrani1, Fatemeh Nejad Maghsoudi2

  • 1Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Iranian Journal of Microbiology
|February 1, 2023
PubMed
Abstract

Insights

Levofloxacin improved symptoms and reduced hospitalization for community-acquired pneumonia (CAP) compared to a beta-lactam and macrolide combination, with similar side effect rates.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Respiratory Medicine

Background:

  • Community-acquired pneumonia (CAP) is a common respiratory infection.
  • Antibiotic treatment is crucial for managing CAP.
  • Comparing different antibiotic regimens is essential for optimizing patient outcomes.

Purpose of the Study:

  • To compare the efficacy and safety of levofloxacin versus a beta-lactam and macrolide combination for mild to moderate CAP.
  • To evaluate clinical signs, symptoms, hospitalization duration, and side effects of two common antibiotic regimens.

Main Methods:

  • Randomized study of patients with mild to moderate CAP.
  • Group I: Ceftriaxone (1g daily) plus Azithromycin (500mg daily) for 5-7 days.
  • Group II: Levofloxacin (750mg daily) for 5 days.

Main Results:

  • Levofloxacin group (Group II) showed significantly better vital signs by day 3 (except temperature) and improved O2 saturation by day 5.
  • Group II demonstrated superior clinical symptom improvement and shorter hospitalization length.
  • The incidence of side effects was comparable between the two groups (P=0.885).

Conclusions:

  • Levofloxacin may offer advantages over the ceftriaxone-azithromycin combination for mild to moderate CAP.
  • Fluoroquinolone therapy can enhance symptom resolution and reduce hospital stay.
  • Both regimens exhibited similar safety profiles regarding side effects.
Keywords:
Anti-bacterial agentsCeftriaxoneClinical trialCommunity-acquired infectionsLevofloxacinMacrolidesPneumonia

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
26
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
413
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such...
31
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
338
Acute Pharyngitis01:30

Acute Pharyngitis

Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
1.2K
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
114